We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
Albemarle (ALB - Free Report) closed at $57.39 in the latest trading session, marking a +1.27% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow gained 0.78%, while the tech-heavy Nasdaq added 0.64%.
The specialty chemicals company's stock has dropped by 24.67% in the past month, falling short of the Basic Materials sector's loss of 4.43% and the S&P 500's loss of 3.56%.
The investment community will be paying close attention to the earnings performance of Albemarle in its upcoming release. The company is slated to reveal its earnings on April 30, 2025. The company's upcoming EPS is projected at -$0.37, signifying a 242.31% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $1.2 billion, reflecting a 11.86% fall from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.05 per share and a revenue of $5.02 billion, signifying shifts of +97.86% and -6.69%, respectively, from the last year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Albemarle. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 14.29% fall in the Zacks Consensus EPS estimate. Albemarle presently features a Zacks Rank of #3 (Hold).
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 204, putting it in the bottom 18% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Albemarle (ALB) Outperforms Broader Market: What You Need to Know
Albemarle (ALB - Free Report) closed at $57.39 in the latest trading session, marking a +1.27% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow gained 0.78%, while the tech-heavy Nasdaq added 0.64%.
The specialty chemicals company's stock has dropped by 24.67% in the past month, falling short of the Basic Materials sector's loss of 4.43% and the S&P 500's loss of 3.56%.
The investment community will be paying close attention to the earnings performance of Albemarle in its upcoming release. The company is slated to reveal its earnings on April 30, 2025. The company's upcoming EPS is projected at -$0.37, signifying a 242.31% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $1.2 billion, reflecting a 11.86% fall from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.05 per share and a revenue of $5.02 billion, signifying shifts of +97.86% and -6.69%, respectively, from the last year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Albemarle. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 14.29% fall in the Zacks Consensus EPS estimate. Albemarle presently features a Zacks Rank of #3 (Hold).
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 204, putting it in the bottom 18% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.